[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349895-105":59,"doc-detail-349895-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","incretin-mimetics-in-cancer-and-cardiovascular-disease-jacc-cardiooncology-state-of-the-art-review","Incretin Mimetics in Cancer and Cardiovascular Disease - JACC: CardioOncology State-of-the-Art Review","","Incretin mimetics, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, have transformed management of obesity, diabetes, and cardiovascular risk. Elevated cancer risk overlaps with these metabolic phenotypes, and limited research suggests possible links to lower risk for some cancers. Cancer patients were excluded from trials, leaving uncertainty about effects on adipose tissue, muscle, risk factors, and outcomes. This review synthesizes current translational and clinical evidence while calling for more randomized data to identify benefit or harm.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/incretin-mimetics-in-cancer-and-cardiovascular-disease-jacc-cardiooncology-state-of-the-art-review/349895/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/incretin-mimetics-in-cancer-and-cardiovascular-disease-jacc-cardiooncology-state-of-the-art-review/349895.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are incretin mimetics and which conditions are they mainly used to address?","Question",{"text":113,"@type":114},"Incretin mimetics include GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. They are paradigm changing for managing obesity, diabetes, and cardiovascular risk.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is cancer-related evidence considered uncertain for incretin mimetics?",{"text":118,"@type":114},"Patients with cancer were excluded from incretin mimetic trials, so effects on adipose tissue, muscle, and cardiometabolic outcomes in this population remain unknown.",{"name":120,"@type":111,"acceptedAnswer":121},"What does the review aim to determine regarding patients receiving cancer treatment?",{"text":122,"@type":114},"The review summarizes evidence on potential effects of incretin mimetics and highlights the need for more data to clarify which patients might benefit or experience harm, including cardiometabolic benefits despite competing cancer death risk.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349895,1790507784,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","J A C C : C A R D I O O N C O L O GY V O L . 8 , N O . 1 , 2 0 2 6  \nª 2 0 2 6 T H E A U T H O R S . P U B L I S H E D BY E L S E V I E R O N B E H A L F O F T H E A M E R I C A N  \nC O L L E G E O F C A R D I O L O GY F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E RT H E C C B Y-N C-N D L I C E N S E ( [h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y-n c-n d / 4 . 0 /](h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y-n c-n d / 4 . 0 /) ) .  \nSTATE-OF-THE-ART REVIEW  \nIncretin Mimetics in Cancer and Cardiovascular Disease  \nJACC: CardioOncology State-of-the-Art Review  \nDarryl Leong, MBBS, MPH, MBIOSTAT, PHD,a Selena Gong, BHSC,b Naveed Sattar, MB, CHB, PHD,c  \nVivek Narayan, MD, MSCE,d Natalie M. Reizine, MD,e Hertzel Gerstein, MD, MSC,a Jordan Vellky, PHDf  \nABSTRACT  \nIncretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for numerous cancers. Limited research suggests that incretin mimetics may be associated with lower risk for developing several cancers. However, more translational and randomized clinical data are needed for confirmation. Patients with cancer were excluded from trials of incretin mi  \nmetics. Therefore, their effects on adipose tissue, muscle, cardiovascular risk factors, and outcomes in this population are unknown. Notwithstanding contraindications with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, translational data also promote the hypothesis that incretin mimetics could slow the growth of other cancers. Further clinical data are needed to determine which patients undergoing cancer treatment might experience benefit or harm from the anthropometric and calorie reduction effects of incretin mimetics or display cardiometabolic benefit despite the competing risk for cancer death. (JACC CardioOncol. 2026;8:1–16) © 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nN  \nearly 100 years ago, Zunz and La Barre1 discovered incretins when they purified the glucose-lowering component of gut ex-  \ntracts. So called because of the incremental insulinogenic effects of oral glucose over intravenous glucose, 2 endogenous incretins, gastric inhibitory polypeptide (later renamed glucose-dependent insulinotropic polypeptide [GIP])2 and glucagon-like peptide-1 (GLP-1), were isolated3 decades later.  \nThe subsequent development of exogenous GLP-1 receptor agonists (RAs), which are more resistant to enzymatic degradation than endogenous GLP-1, and, more recently, dual agonists (GLP-1/GIP RAs), have led to an exponential expansion of research into how these molecular mechanisms might be exploited. Initially, this research identified clinically important metabolic, weight-related, renal, and cardiovascular benefits of these drugs in people with diabetes. These  \nFrom aThe Population Health Research Institute and Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; bThe Royal College of Surgeons of Ireland, Dublin, Ireland; cSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; dDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; eUniversity of Illinois Cancer Center and Department of Medicine, University of Illinois at Chicago, Chicago, USA; and the fDepartment of Pathology, University of Illinois at Chicago, Chicago, USA.  \nRonald Witteles, MD, Deputy Editor, served as Acting Editor-in-Chief for this paper.  \nThe authors at","cbCaigoKEHGrguvE","https://ap.wps.com/l/cbCaigoKEHGrguvE","pdf",1649376,16,"English","# Abstract\n# Background and discovery of incretins\n# Mechanisms and development of incretin mimetics\n# Rationale for cancer-focused evidence\n# Review purpose and evidence gaps","[{\"question\":\"What are incretin mimetics and which conditions are they mainly used to address?\",\"answer\":\"Incretin mimetics include GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. They are paradigm changing for managing obesity, diabetes, and cardiovascular risk.\"},{\"question\":\"Why is cancer-related evidence considered uncertain for incretin mimetics?\",\"answer\":\"Patients with cancer were excluded from incretin mimetic trials, so effects on adipose tissue, muscle, and cardiometabolic outcomes in this population remain unknown.\"},{\"question\":\"What does the review aim to determine regarding patients receiving cancer treatment?\",\"answer\":\"The review summarizes evidence on potential effects of incretin mimetics and highlights the need for more data to clarify which patients might benefit or experience harm, including cardiometabolic benefits despite competing cancer death risk.\"}]","Incretin Mimetics in Cancer and Cardiovascular Disease - JACC: CardioOncology State-of-the-Art Review | PDF",1790086112,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fa193df7d699d26c5fcec5861c78d8e.webp",983,1320,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8937c662de2006c8afa2b2a6cbc46173.webp",982,1319,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25ae30c5d6a7ceae16e15de117008f80.webp",981,1318,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61d8ca787bc7c5cd9d9735f768f4f27a.webp",980,1316]